Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurent Greillier

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Lung Cancer (Amsterdam, Netherlands)|July 14, 2024
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study)Mathilde Jacob, Pierre Fournel, Claire Tissot, et al.
The New England Journal of Medicine|May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsCaicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
The European Respiratory Journal|May 27, 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesotheliomaArnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung CancerGlenwood D Goss, Gail E Darling, Virginie Westeel, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|May 26, 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesotheliomaIsabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, et al.
Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus ReportAnne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.
The Lancet. Respiratory Medicine|June 27, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trialDavid R Spigel, Virginie Westeel, Ian C Anderson, et al.
Lung Cancer (Amsterdam, Netherlands)|July 14, 2024
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study)Mathilde Jacob, Pierre Fournel, Claire Tissot, et al.
The New England Journal of Medicine|May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion MutationsCaicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
The European Respiratory Journal|May 27, 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesotheliomaArnaud Scherpereel, Isabelle Opitz, Thierry Berghmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung CancerGlenwood D Goss, Gail E Darling, Virginie Westeel, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|May 26, 2020
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesotheliomaIsabelle Opitz, Arnaud Scherpereel, Thierry Berghmans, et al.
Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus ReportAnne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
Journal for Immunotherapy of Cancer|June 19, 2026
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumorsKristoffer Staal Rohrberg, Ignacio Melero, Miguel F Sanmamed, et al.
Pageof 16